Patients ( n = 1495 ) with cT 3 tumors , or negative hormone-receptor status , or positive hormone-receptor and clinically node-positive disease received four times epirubicin/cyclophosphamide and were thereafter randomly assigned to four times docetaxel ( Taxotere ) , or four times docetaxel/capecitabine over 24 weeks , or four times docetaxel followed by capecitabine over 36 weeks .